Study S001294

Short- and Long-term Effects of Once Weekly Semaglutide 2.4 mg on Appetite, Eating Behavior, and Psychosocial Status

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan (PDF)

Registration

Registration: NCT05548647
Acronym: STABLE Wt Loss
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 120
Start: 2022-07-26
Primary completion: 2025-05-12
Lead sponsor: University of Pennsylvania
Conditions: Obesity
Interventions: BEHAVIORAL:Behavioral Treatment; DRUG:Placebo; DRUG:Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]
Results posted: TRUE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Study 1 Ad Libitum Energy Intake (kcal) During a Buffet Lunch Meal (4 Hrs After Standardized Breakfast) [S1: Change from baseline to weeks 20, 40, and 60]
Study 2 Ad Libitum Energy Intake (kcal) During a Buffet Lunch Meal (4 Hrs After Standardized Breakfast) [S2: Endpoint comparison at week 72]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0013679	Short- and long-term effects of semaglutide 2.4 mg on energy intake, appetite, and food reward: a 60-week, double-blind randomized controlled trial. Tronieri JS, The American journal of clinical nutrition	2026	Randomized trial	PMID 42323166 DOI	cites ClinicalTrials.gov:NCT05548647; registry reference DERIVED:42323166